← TrialMatch
HomeTrials

Improving Cognition Through Telehealth Aerobic Exercise and Cognitive Training After a Fir

The participants in the study will receive psychiatric treatment at the UCLA Aftercare Research Program. All participants in this 12-month RCT will receive cognitive training. Half of the patients will also be randomly assigned to the aerobic exercise and strength training condition, and the other half will be randomly

Condition(s)Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
StatusRecruiting
PhaseNA
Study typeInterventional
SummaryThe participants in the study will receive psychiatric treatment at the UCLA Aftercare Research Program. All participants in this 12-month RCT will receive cognitive training. Half of the patients will also be randomly assigned to the aerobic exercise and strength training condition, and the other half will be randomly assigned to the Healthy Living Group condition. The primary outcome measures are improvement in cognition and level of engagement in the in-group and at-home exercise sessions. Increases in the level of the patient's serum brain-derived neurotropic factor (specifically Mature BDNF) which causes greater brain neuroplasticity and is indicator of engagement in aerobic exercise, will be measured early in the treatment phase in order to confirm engagement of this target. In order
Who can participateInclusion Criteria: 1. a first episode of a psychotic illness that began within the past three years; 2. a diagnosis by DSM-5 of schizophrenia, schizoaffective disorder, or schizophreniform disorder; 3. age 18 to 45 years of age; 4. sufficient acculturation and fluency in the English language to avoid invalidating research measures; and 5. residence likely to be within commuting distance of the UCLA Aftercare Research Program. Exclusion Criteria: 1. premorbid IQ less than 70; 2. evidence of a known neurological disorder (e.g., epilepsy) or significant head injury; 3. evidence of moderate or severe substance use disorder within the six months prior to the first episode or evidence of a substance-induced psychosis.
Ages18 Years to 45 Years
SexAll
Lead sponsorUniversity of California, Los Angeles
LocationsLos Angeles, California, United States
Start date2023-05-23
NCT IDNCT05890183
Official listinghttps://clinicaltrials.gov/study/NCT05890183

🔍 Search all trials →